Skip to content

The clinical study on the use of different effect-site concentration of remifentanil combined with transcutaneous electrical acupoint stimulation to reduce the dosage of propofol

The clinical study on the use of different effect-site concentration of remifentanil combined with transcutaneous electrical acupoint stimulation to reduce the dosage of propofol

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014987
Enrollment
Unknown
Registered
2018-02-26
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung tumor

Interventions

Group 1:remifentanil 4ng/ml+apply transcutaneous electrical acupoint stimulation on Leique+Quchi+Hegu+Neiguan
Group 2:remifentanil 6ng/ml+apply transcutaneous electrical acupoint stimulation on Leique+Quchi+Hegu+Neiguan
Group 3:remifentanil 4ng/ml+apply plates on acupoints
Group 4:remifentanil 6ng/ml+apply plates on acupoints

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. To be diagnosed as lung tumor, planed to receive selective single-sided VATS lobectomy, the operation is expected to be over 90 minutes; 2. Patient to be written an informed consent; 3. Age 18 -65 years old, male or female; 4. ASA grade I-II; 5. BMI 18kg/m2 to 30kg/m2.

Exclusion criteria

Exclusion criteria: 1. Central nervous system disease; 2. Preoperative use of any drugs known to affect EEG, such as antipsychotics, sedatives, antiepileptic drugs, central nervous stimulants, including alcoholism; 3. Patients who are known to be allergic to propofol and remifentanil; 4. History of chronic opiate abuse; 5. recent use of TEAS or acupuncture, and neural damage or infection along the meridian on which the acupoints lay. 6. History of severe cardiovascular, respiratory, liver, kidney, adrenal, hypothalamic pituitary or muscle disease; 7. Abnormal function of liver, renal function and coagulation; 8. Uncontrolled or difficult to control hypertension: non-invasive systolic blood pressure (SBP) is greater than 160mmHg or non-invasive diastolic blood pressure (DBP) is greater than 100mmHg.

Design outcomes

Primary

MeasureTime frame
the dosage of propofol (mg/kg/h);globe score (GS);

Secondary

MeasureTime frame
Satisfactory anesthesia time;Duration of deep anesthesia (BIS60);

Countries

China

Contacts

Public ContactZuo mingzhang

Beijing Hospital

zuomz@163.com+86 13911589738

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026